Superluminal Medicines Launches With $33 Million Seed Round To Fuel Its Drug Discovery Engine And Pipeline Of Small Molecule Therapeutics

Aug 28, 2023•over 2 years ago

Amount Raised

$33 Million

Round Type

seed

BostonBiotechnology

Description

Superluminal Medicines Inc., a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created, today announced the closing of a $33 million funding round. The investment was led by RA Capital Management with significant participation from Insight Partners and NVIDIA. Gaingels also joined in the financing.

Company Information

Company

Superluminal Medicines

Location

Boston, Massachusetts, United States

About

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Superluminal Medicines Launches With $33 Million Seed Round To Fuel Its Drug Discovery Engine And Pipeline Of Small Molecule Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information